Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 19

recruiting
3 987
countries
28
conditions
2 109

4 491 trials match your criteria

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib

Cataract

Recruiting

Study of levofloxacin, ketorolac trometamol, and dexamethasone eye drops for preventing inflammation and infection after cataract surgery in adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Oesophageal adenocarcinoma

Recruiting

Study of PF-08634404 with chemotherapy drug combination in previously untreated patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Interstitial lung disease

Recruiting

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:BI 1015550

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Adenocarcinoma pancreas

Recruiting

Safety Study of VCN-01 with nab‑Paclitaxel and Gemcitabine in Newly Diagnosed Metastatic Pancreatic Cancer Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Genetically modified human adenovirus encoding human PH20 hyaluronidase

Neuroblastoma

Recruiting

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Irinotecan

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.